Printed from Voxsanity (voxsanity.com.au) — NCT07618793 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Not Yet Recruiting
NCT07618793
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 to 75 years old (inclusive), of any sex.
- People who have been diagnosed with a specific type of lung cancer called squamous cell lung carcinoma, confirmed by tissue testing, at stage II or IIIA (using a standard staging system called AJCC 8th edition).
- People whose main lung tumour has been reviewed by a team of specialists and judged to be fully removable by surgery.
- People who are generally active and able to carry out daily activities, with a health performance score of 0 or 1 on a standard medical scale (meaning fully active or restricted only in physically demanding tasks).
- People with a life expectancy of at least 6 months.
- People whose blood, organ, and clotting functions fall within acceptable ranges on blood tests taken within 7 days before joining, specifically: a neutrophil count of at least 1.5 x 10⁹/L; a platelet count of at least 100 x 10⁹/L; a haemoglobin level of at least 90 g/L; a total bilirubin level no more than 1.5 times the upper limit of normal; liver enzyme levels (ALT and AST) no more than 2.5 times the upper limit of normal; a creatinine level no more than 1.5 times the upper limit of normal, or a creatinine clearance of at least 50 mL/min; and clotting measures (INR and APTT) no more than 1.5 times the upper limit of normal.
- Women who could become pregnant must have a negative blood pregnancy test within 7 days before the first dose, and must agree to use effective contraception during the study and for at least 6 months after the last dose; men must also agree to use effective contraception during the study and for at least 6 months after the last dose.
- People who understand the study, choose to take part voluntarily, and sign a written consent form.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose lung cancer has been confirmed by tissue testing to be small cell lung cancer, adeno-squamous carcinoma, large cell neuroendocrine carcinoma, or adenocarcinoma, including cancers that contain any of these elements.
- People whose cancer has certain gene mutations or changes (such as EGFR, ALK, or ROS1) for which approved targeted treatments are already available.
- People who have previously received any systemic treatment for lung cancer, including chemotherapy, radiation therapy, immunotherapy, targeted therapy, or surgery to remove the tumour.
- People who have an active, known, or suspected autoimmune disease (such as lupus, rheumatoid arthritis, inflammatory bowel disease, or autoimmune hepatitis), or who have had an autoimmune disease within the past 2 years.
- People who have had another cancer in the past 5 years, except for certain fully treated skin cancers or early-stage cancers confined to one area (such as cervical carcinoma in situ).
- People with serious heart or blood vessel conditions, including a heart attack or unstable chest pain in the past 6 months; severe heart failure (Class III or IV on a standard medical scale); significant or poorly controlled irregular heartbeat; or a stroke or mini-stroke in the past 6 months.
- People with high blood pressure that remains poorly controlled (readings of 160 mmHg or higher for the top number, and/or 100 mmHg or higher for the bottom number) despite standard blood pressure medication.
- People with chronic obstructive pulmonary disease (COPD) or other breathing conditions that have severely reduced lung function (for example, a breathing test result below 50% of the expected value, or a need for ongoing home oxygen therapy).
- People who have an active infection requiring intravenous antibiotic or antiviral treatment in the 2 weeks before joining the trial (such as severe pneumonia or a bloodstream infection), or who have active tuberculosis.
- People with a known history of HIV infection, or who have active Hepatitis B or active Hepatitis C (based on specific blood test thresholds).
- People with a history of interstitial lung disease, lung inflammation caused by medication, lung inflammation from radiation that required steroid treatment, or signs of current active lung inflammation.
- People with severe claustrophobia, a history of severe altitude sickness, or any other medical or psychological condition that would prevent safe participation in the intermittent hypoxic training sessions using the study's specialised low-oxygen equipment (FLY-2265 system).
- Women who are pregnant or breastfeeding.
- People who have any other medical condition, abnormal test result, or personal circumstance that the trial doctor believes could affect their safety, interfere with the study results, or make it difficult to follow the study procedures.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Phone: +86-13141370703
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
zhang yi
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
1 December 2027
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Pathologic Complete Response (pCR) Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.